Title: LegoChem's antibiotics selected for Korea Drug Development Fund's new drug project

Publication: Daedeoket

Date: 28 February 2013

Summary

• Antibiotics for Gram-negative bacteria, LCB10-0200, was selected for “Korea Drug Development Fund”.

• 50% of development costs will be funded for next 16 months for non-clinical study to be conducted in the United States or Europe.

• Head of Antibiotics, Dr. Young-Lag Cho said, “we hope to discover a global blockbuster drug by combine out LCB10-0200 with AstraZeneca’s beta-lactamase inhibitor.”

• LegoChem’s another drug, Oxazolidinone antibiotics, was also selected for ‘Korea Drug Development Fund” which is now on clinical study phase 1.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).